Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Luprolide Clear all
Completed Phase 2 Interventional Results available

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

NCT02903368
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

NCT00170157
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

NCT05873192
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT, Enzalutamide, Talazoparib, Degarelix, Luprolide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT04734730
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

NCT01344564
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix acetate, Leuprolide acetate
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 2, 2026, 4:23 AM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

NCT03649724
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

NCT03902951
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer

NCT00223665
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 2, 2026, 4:23 AM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

NCT00514917
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Leuprolide, Bicalutamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 2, 2026, 4:23 AM EDT
Not yet recruiting Phase 2 Interventional

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

NCT07650240
View directory record Official record
Conditions
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

NCT05617885
View directory record Official record
Conditions
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
Interventions
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Drug
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Bicalutamide, Cixutumumab, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Pharmacological Study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
169
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 2, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

NCT01431391
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
Interventions
sipuleucel-T, leuprolide acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
14
States / cities
Homewood, Alabama • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00544830
View directory record Official record
Conditions
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Leuprolide Acetate
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

NCT06169124
View directory record Official record
Conditions
Adult Ovarian Granulosa Cell Tumor
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Darolutamide, Exemestane, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
66
States / cities
Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 2, 2026, 4:23 AM EDT